Stock KRYS KRYSTAL BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
156.9 USD +0.77% Intraday chart for Krystal Biotech, Inc. -1.04% +26.45%
22/04 Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung CI
16/04 Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 958.5 1,182 1,742 2,040 3,499 4,473 - -
Enterprise Value (EV) 1 774.3 918.1 1,304 1,661 2,905 3,910 3,734 3,388
P/E ratio -46.2 x -35.1 x -22.3 x -14.4 x 318 x 82.6 x 30.7 x 18.4 x
Yield - - - - - - - -
Capitalization / Revenue - - - - 69 x 17.2 x 10.6 x 7.39 x
EV / Revenue - - - - 57.3 x 15 x 8.82 x 5.6 x
EV / EBITDA -36.3 x -29.5 x -19.9 x -11.5 x -27.4 x 59 x 23.1 x 10.8 x
EV / FCF - -22.4 x -11.2 x -10.8 x -28.9 x 36.7 x 16.2 x 10.1 x
FCF Yield - -4.46% -8.92% -9.25% -3.46% 2.72% 6.15% 9.89%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 17,308 19,708 24,906 25,748 28,206 28,515 - -
Reference price 2 55.38 60.00 69.95 79.22 124.1 156.9 156.9 156.9
Announcement Date 10/03/20 01/03/21 28/02/22 27/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - 50.7 260 423.3 605.6
EBITDA 1 -21.33 -31.15 -65.51 -144.1 -106 66.31 161.4 312.9
EBIT 1 -22.08 -33 -68.28 -145.2 -109.7 43.65 165.6 307.6
Operating Margin - - - - -216.43% 16.79% 39.11% 50.8%
Earnings before Tax (EBT) 1 -19.09 -32.17 -69.57 -140 12.9 65.31 196.8 334.5
Net income 1 -19.09 -32.17 -69.57 -140 10.93 46.06 146.1 264.2
Net margin - - - - 21.56% 17.71% 34.52% 43.63%
EPS 2 -1.200 -1.710 -3.130 -5.490 0.3900 1.899 5.114 8.537
Free Cash Flow 1 - -40.93 -116.3 -153.5 -100.6 106.5 229.8 335
FCF margin - - - - -198.43% 40.96% 54.3% 55.31%
FCF Conversion (EBITDA) - - - - - 160.6% 142.39% 107.06%
FCF Conversion (Net income) - - - - - 231.22% 157.3% 126.76%
Dividend per Share 2 - - - - - - - -
Announcement Date 10/03/20 01/03/21 28/02/22 27/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - 8.556 42.14 47.42 60.55 71.72 80.51 -
EBITDA 1 - -21.09 - - - - - - - 4.298 18.25 33.83 45.59 51.52 -
EBIT 1 -15.65 -21.88 -25.22 -28.75 -31.45 -34.77 -48.82 -38.05 -25.99 3.138 1.506 9.099 19.54 21.11 -
Operating Margin - - - - - - - - -303.8% 7.45% 3.18% 15.03% 27.24% 26.22% -
Earnings before Tax (EBT) 1 -15.59 -21.81 -49.96 -28.11 -29.85 -32.05 -45.3 -33.21 80.75 10.66 4.744 15.25 22.3 25.64 -
Net income 1 -15.59 -21.81 -49.96 -28.11 -29.85 -32.05 -45.3 -33.21 80.75 8.692 4.086 12.4 18.02 20.45 -
Net margin - - - - - - - - 943.75% 20.63% 8.62% 20.48% 25.12% 25.39% -
EPS 2 -0.7000 -0.9500 -1.990 -1.100 -1.170 -1.250 -1.760 -1.250 2.790 0.3100 0.1457 0.3183 0.6314 0.6586 0.7200
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 08/11/21 28/02/22 09/05/22 08/08/22 07/11/22 27/02/23 08/05/23 07/08/23 06/11/23 26/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 184 264 438 379 594 564 739 1,085
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -40.9 -116 -154 -101 107 230 335
ROE (net income / shareholders' equity) - - -15.7% -25.1% -11.4% 13.1% 20.8% 19.1%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share 2 - - -2.160 -3.950 -3.200 2.810 3.890 -
Capex 1 - 14.8 68.3 0.05 11.8 8 10 -
Capex / Sales - - - - 23.27% 3.08% 2.36% -
Announcement Date 10/03/20 01/03/21 28/02/22 27/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Krystal Biotech, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
156.9 USD
Average target price
188.5 USD
Spread / Average Target
+20.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
KRYSTAL BIOTECH, INC. Stock Krystal Biotech, Inc.
+26.45% 4.47B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. KRYS Stock
  4. Financials Krystal Biotech, Inc.